Valerie's story
Every time a case of breast cancer is diagnosed, there is somebody behind it whose life will change. And they have inspirational, emotional stories to tell. Here is the story of one woman who made the switch to AROMASIN® (exemestane tablets).
An inspiring breast cancer survivor, Valerie underwent chemotherapy and soon became proactive in learning about adjuvant treatment. She tells of her partnership with her doctor and how together they made the right choices to help treat her breast cancer. Now she's sharing her story of why she switched to AROMASIN.
Select a question to hear Valerie’s response.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
